JOHNSON & JOHNSON (JNJ) Fundamental Analysis & Valuation
NYSE:JNJ • US4781601046
Current stock price
243.04 USD
-1.08 (-0.44%)
At close:
243.04 USD
0 (0%)
After Hours:
This JNJ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. JNJ Profitability Analysis
1.1 Basic Checks
- JNJ had positive earnings in the past year.
- JNJ had a positive operating cash flow in the past year.
- In the past 5 years JNJ has always been profitable.
- In the past 5 years JNJ always reported a positive cash flow from operatings.
1.2 Ratios
- JNJ has a better Return On Assets (13.46%) than 94.79% of its industry peers.
- JNJ's Return On Equity of 32.87% is amongst the best of the industry. JNJ outperforms 94.79% of its industry peers.
- JNJ has a Return On Invested Capital of 14.37%. This is amongst the best in the industry. JNJ outperforms 93.75% of its industry peers.
- JNJ had an Average Return On Invested Capital over the past 3 years of 16.34%. This is above the industry average of 13.06%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.46% | ||
| ROE | 32.87% | ||
| ROIC | 14.37% |
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)16.34%
ROIC(5y)15%
1.3 Margins
- With an excellent Profit Margin value of 28.46%, JNJ belongs to the best of the industry, outperforming 94.27% of the companies in the same industry.
- In the last couple of years the Profit Margin of JNJ has grown nicely.
- JNJ has a better Operating Margin (27.78%) than 93.23% of its industry peers.
- JNJ's Operating Margin has improved in the last couple of years.
- JNJ has a Gross Margin of 67.92%. This is in the better half of the industry: JNJ outperforms 76.04% of its industry peers.
- In the last couple of years the Gross Margin of JNJ has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.78% | ||
| PM (TTM) | 28.46% | ||
| GM | 67.92% |
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
2. JNJ Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), JNJ is creating some value.
- Compared to 1 year ago, JNJ has about the same amount of shares outstanding.
- JNJ has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, JNJ has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 5.09 indicates that JNJ is not in any danger for bankruptcy at the moment.
- The Altman-Z score of JNJ (5.09) is better than 77.08% of its industry peers.
- JNJ has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as JNJ would need 2.43 years to pay back of all of its debts.
- The Debt to FCF ratio of JNJ (2.43) is better than 92.71% of its industry peers.
- JNJ has a Debt/Equity ratio of 0.56. This is a neutral value indicating JNJ is somewhat dependend on debt financing.
- JNJ has a worse Debt to Equity ratio (0.56) than 65.10% of its industry peers.
- Even though the debt/equity ratio score it not favorable for JNJ, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | 5.09 |
ROIC/WACC1.51
WACC9.51%
2.3 Liquidity
- JNJ has a Current Ratio of 1.03. This is a normal value and indicates that JNJ is financially healthy and should not expect problems in meeting its short term obligations.
- JNJ has a Current ratio of 1.03. This is amonst the worse of the industry: JNJ underperforms 83.85% of its industry peers.
- JNJ has a Quick Ratio of 1.03. This is a bad value and indicates that JNJ is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of JNJ (0.77) is worse than 84.38% of its industry peers.
- JNJ does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.03 | ||
| Quick Ratio | 0.77 |
3. JNJ Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 8.11% over the past year.
- JNJ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.11% yearly.
- The Revenue has been growing slightly by 6.05% in the past year.
- JNJ shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.67% yearly.
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%
3.2 Future
- The Earnings Per Share is expected to grow by 8.75% on average over the next years. This is quite good.
- The Revenue is expected to grow by 6.02% on average over the next years.
EPS Next Y7.85%
EPS Next 2Y8.27%
EPS Next 3Y8.5%
EPS Next 5Y8.75%
Revenue Next Year7.19%
Revenue Next 2Y6.53%
Revenue Next 3Y6.26%
Revenue Next 5Y6.02%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. JNJ Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 22.50 indicates a rather expensive valuation of JNJ.
- Based on the Price/Earnings ratio, JNJ is valued cheaper than 81.25% of the companies in the same industry.
- When comparing the Price/Earnings ratio of JNJ to the average of the S&P500 Index (25.60), we can say JNJ is valued inline with the index average.
- The Price/Forward Earnings ratio is 20.87, which indicates a rather expensive current valuation of JNJ.
- 77.60% of the companies in the same industry are more expensive than JNJ, based on the Price/Forward Earnings ratio.
- The average S&P500 Price/Forward Earnings ratio is at 22.84. JNJ is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.5 | ||
| Fwd PE | 20.87 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, JNJ is valued cheaper than 80.21% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, JNJ is valued cheaper than 82.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.72 | ||
| EV/EBITDA | 17.7 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- JNJ has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.87
PEG (5Y)3.69
EPS Next 2Y8.27%
EPS Next 3Y8.5%
5. JNJ Dividend Analysis
5.1 Amount
- JNJ has a Yearly Dividend Yield of 2.17%.
- Compared to an average industry Dividend Yield of 0.68, JNJ pays a better dividend. On top of this JNJ pays more dividend than 93.23% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.88, JNJ has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.17% |
5.2 History
- The dividend of JNJ is nicely growing with an annual growth rate of 7.68%!
- JNJ has paid a dividend for at least 10 years, which is a reliable track record.
- JNJ has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)7.68%
Div Incr Years34
Div Non Decr Years34
5.3 Sustainability
- JNJ pays out 46.19% of its income as dividend. This is a bit on the high side, but may be sustainable.
- JNJ's earnings are growing around the same pace than its dividend. As long as the earnings growth is kept the dividend growth is sustainable.
DP46.19%
EPS Next 2Y8.27%
EPS Next 3Y8.5%
JNJ Fundamentals: All Metrics, Ratios and Statistics
243.04
-1.08 (-0.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21 2026-01-21/bmo
Earnings (Next)04-14 2026-04-14
Inst Owners75.62%
Inst Owner Change4.68%
Ins Owners0.04%
Ins Owner Change4.13%
Market Cap585.39B
Revenue(TTM)94.19B
Net Income(TTM)26.80B
Analysts75.63
Price Target244.4 (0.56%)
Short Float %0.97%
Short Ratio2.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.17% |
Yearly Dividend5.14
Dividend Growth(5Y)7.68%
DP46.19%
Div Incr Years34
Div Non Decr Years34
Ex-Date02-24 2026-02-24 (1.3)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.21%
Min EPS beat(2)-0.13%
Max EPS beat(2)0.55%
EPS beat(4)3
Avg EPS beat(4)2.17%
Min EPS beat(4)-0.13%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.84%
EPS beat(12)10
Avg EPS beat(12)3.23%
EPS beat(16)14
Avg EPS beat(16)3.09%
Revenue beat(2)2
Avg Revenue beat(2)0.35%
Min Revenue beat(2)0.03%
Max Revenue beat(2)0.67%
Revenue beat(4)4
Avg Revenue beat(4)1.04%
Min Revenue beat(4)0.03%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.32%
Revenue beat(12)8
Avg Revenue beat(12)-0.5%
Revenue beat(16)8
Avg Revenue beat(16)-4.44%
PT rev (1m)3.42%
PT rev (3m)14.83%
EPS NQ rev (1m)-0.07%
EPS NQ rev (3m)-3.17%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-0.08%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)1.86%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)1.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.5 | ||
| Fwd PE | 20.87 | ||
| P/S | 6.21 | ||
| P/FCF | 29.72 | ||
| P/OCF | 23.86 | ||
| P/B | 7.18 | ||
| P/tB | N/A | ||
| EV/EBITDA | 17.7 |
EPS(TTM)10.8
EY4.44%
EPS(NY)11.65
Fwd EY4.79%
FCF(TTM)8.18
FCFY3.36%
OCF(TTM)10.18
OCFY4.19%
SpS39.11
BVpS33.86
TBVpS-7.32
PEG (NY)2.87
PEG (5Y)3.69
Graham Number90.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.46% | ||
| ROE | 32.87% | ||
| ROCE | 18.03% | ||
| ROIC | 14.37% | ||
| ROICexc | 16.57% | ||
| ROICexgc | 67.45% | ||
| OM | 27.78% | ||
| PM (TTM) | 28.46% | ||
| GM | 67.92% | ||
| FCFM | 20.91% |
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)16.34%
ROIC(5y)15%
ROICexc(3y)19.6%
ROICexc(5y)18.23%
ROICexgc(3y)74.51%
ROICexgc(5y)73.44%
ROCE(3y)20.24%
ROCE(5y)18.7%
ROICexgc growth 3Y3.9%
ROICexgc growth 5Y-2.01%
ROICexc growth 3Y8.52%
ROICexc growth 5Y5.62%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 1.36 | ||
| Cap/Depr | 64.4% | ||
| Cap/Sales | 5.13% | ||
| Interest Coverage | 6.81 | ||
| Cash Conversion | 72.86% | ||
| Profit Quality | 73.49% | ||
| Current Ratio | 1.03 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 5.09 |
F-Score4
WACC9.51%
ROIC/WACC1.51
Cap/Depr(3y)61.79%
Cap/Depr(5y)58.46%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.02%
Profit Quality(3y)88.82%
Profit Quality(5y)91.38%
High Growth Momentum
Growth
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
EPS Next Y7.85%
EPS Next 2Y8.27%
EPS Next 3Y8.5%
EPS Next 5Y8.75%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%
Revenue Next Year7.19%
Revenue Next 2Y6.53%
Revenue Next 3Y6.26%
Revenue Next 5Y6.02%
EBIT growth 1Y12.82%
EBIT growth 3Y12.1%
EBIT growth 5Y9.84%
EBIT Next Year23.18%
EBIT Next 3Y11.51%
EBIT Next 5Y8.55%
FCF growth 1Y-0.73%
FCF growth 3Y4.65%
FCF growth 5Y-0.49%
OCF growth 1Y1.09%
OCF growth 3Y4.99%
OCF growth 5Y0.83%
JOHNSON & JOHNSON / JNJ Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for JOHNSON & JOHNSON?
ChartMill assigns a fundamental rating of 6 / 10 to JNJ.
What is the valuation status of JOHNSON & JOHNSON (JNJ) stock?
ChartMill assigns a valuation rating of 5 / 10 to JOHNSON & JOHNSON (JNJ). This can be considered as Fairly Valued.
How profitable is JOHNSON & JOHNSON (JNJ) stock?
JOHNSON & JOHNSON (JNJ) has a profitability rating of 8 / 10.
What is the financial health of JOHNSON & JOHNSON (JNJ) stock?
The financial health rating of JOHNSON & JOHNSON (JNJ) is 6 / 10.
Can you provide the expected EPS growth for JNJ stock?
The Earnings per Share (EPS) of JOHNSON & JOHNSON (JNJ) is expected to grow by 7.85% in the next year.